Semax is a synthetic heptapeptide developed in Russia in the late 1980s and early 1990s as a neuroactive analog of the ACTH(4-10) fragment, engineered to keep the cognitive and neurotrophic activity of that hormone fragment while shedding the cortisol-raising hormonal branch. The honest bottom line sits at the front: in Russia it is a registered medication for conditions such as ischemic stroke and certain optic nerve disorders, but outside Russia and a few neighboring states it holds no approval from major regulators including the US FDA, and it circulates mainly as a research chemical of variable quality supported largely by Russian-language literature that has not been independently replicated at scale.
Semax is a Russia-developed ACTH(4-10)-derived heptapeptide approved as a medication in its country of origin but sold in the United States only as an unapproved research chemical with no FDA recognition.
The published record traces Semax to adrenocorticotropic hormone, and specifically to the ACTH 4-10 fragment that earlier work had tied to learning, attention, and neural repair rather than steroid production. Chemists at the Institute of Molecular Genetics of the Russian Academy of Sciences, working with Moscow State University in the late Soviet period, took that Met-Glu-His-Phe core and appended a Pro-Gly-Pro tail, a design choice that slowed enzymatic degradation enough to make the peptide useful as a drug.
Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, built by adding a Pro-Gly-Pro tail to the ACTH(4-10) fragment to slow enzymatic breakdown.
The mechanism most consistently attributed to Semax in the literature is an increase in brain-derived neurotrophic factor and its receptor TrkB, along with nerve growth factor, particularly in the hippocampus. These are mechanism-level and preclinical findings rather than proven human outcomes, and they form the biological story behind the compound's proposed cognitive and neuroprotective effects. Intranasal delivery is thought to let a portion of the dose reach the brain along olfactory and trigeminal pathways that partly bypass the blood-brain barrier.
The proposed mechanism of Semax centers on raising hippocampal BDNF, TrkB, and NGF while modulating dopaminergic and serotonergic signaling, though this evidence stands mainly at the mechanistic and animal-model level.
The uses attributed to Semax split cleanly into two camps, and the divide between them is exactly where a careful reader slows down. On one side are formal clinical indications recognized in Russia; on the other are informal cognitive-enhancement uses driven by the nootropic community, which generally outrun the strength of the published evidence.
| Use category | Documented context | Evidence standing |
|---|---|---|
| Ischemic stroke | Registered Russian indication in neuroprotective and rehabilitation protocols | Best-documented clinical use, mostly Russian trials |
| Optic nerve disorders | Registered indication for optic neuropathy | Domestic clinical recognition, limited outside replication |
| Pediatric attention and cognition | Explored in Russian practice for attention-deficit presentations | Investigational, small studies |
| Everyday cognitive enhancement | Focus, working memory, verbal fluency, stress resilience | Anecdotal and self-reported, outruns published evidence |
Semax carries registered Russian indications for ischemic stroke and optic nerve disorders, while its widely reported cognitive-enhancement uses remain anecdotal and are not backed by approved-drug-level evidence.
The evidence base for Semax is real but uneven, and its geography matters as much as its content. Most human research consists of Russian clinical studies from the 1990s onward in stroke, cognitive disorders, and optic nerve disease, alongside a substantial body of rodent work on memory, neuroprotection, and gene expression. The animal data are the most mechanistically persuasive part of the literature; the human trials tend to be small and often lack the randomization, blinding, and placebo control that Western regulators expect.
The Semax evidence base rests mainly on rodent studies and small Russian human trials that lack rigorous randomization and independent replication, leaving a credibility gap that agencies such as the FDA have not accepted.
Regulatory status is the sharpest dividing line in the whole Semax story, and it depends entirely on jurisdiction. In Russia and a few neighboring states, Semax is an approved and registered pharmaceutical manufactured to medicinal standards. In the United States it has no FDA approval for any use, is neither an over-the-counter drug nor a recognized dietary supplement ingredient, and cannot be lawfully marketed to diagnose, treat, or prevent any condition.
In the United States Semax has no FDA approval and is sold only as a Research Use Only chemical labeled not for human consumption, a status that leaves buyers without recourse on identity, purity, or safety.
The defining feature of Semax administration in the literature is that it is overwhelmingly given intranasally, as drops or a spray on the nasal mucosa, a route that lets a peptide reach the brain without the digestive breakdown of an oral dose or the needles of an injection. Russian clinical use expresses dosing in micrograms per day divided across each nostril, with higher totals reported in acute neurological settings than in everyday cognitive use. The figures circulating in online communities are anecdotal rather than a medical protocol, since genuine dosing depends on indication, individual, variant, and a product's real concentration and purity.
Semax is documented as an intranasal peptide dosed in micrograms per day split across the nostrils, with online figures being anecdotal rather than a validated medical protocol tied to a specific indication and product purity.
In the studies that exist, Semax is generally described as well tolerated, most often with mild local nasal irritation and, less commonly, headache, blood pressure changes, or transient mood and sleep shifts. That comparatively clean short-term profile sits on top of a large gap, though: there is little rigorous long-term safety data outside the specific Russian indications, and essentially none for the continuous or high-dose self-experimentation seen in nootropic use. The most underappreciated hazard is not the peptide itself but the way it is obtained.
Semax is reported as well tolerated in short-term studies with mainly mild nasal irritation, but it lacks rigorous long-term safety data and its research-chemical sourcing carries real risks of contamination, mislabeling, and inaccurate dosing.
Semax is most often discussed alongside Selank and Noopept, two other compounds from the same Russian peptide-research tradition, and the comparison is instructive because their emphases differ. Selank, a synthetic analog of the immune peptide tuftsin, is oriented toward anxiety and mood and has a calming reputation, whereas Semax leans toward activation, focus, and neuroprotection. Noopept is a synthetic dipeptide-derived compound rather than a peptide analog, orally active, and used purely as a cognitive enhancer without the stroke and optic-nerve clinical framing that surrounds Semax.
| Compound | Origin / class | Primary emphasis | Regulatory reality |
|---|---|---|---|
| Semax | ACTH(4-10) analog, intranasal | Activation, focus, neuroprotection | Approved in Russia, unapproved research chemical in US |
| Selank | Tuftsin analog, intranasal | Anxiety, stress, mood | Approved in Russia, unapproved research chemical in US |
| Noopept | Synthetic dipeptide-derived, oral | Cognitive enhancement | Studied primarily in Russia, unapproved research chemical in US |
Semax, Selank, and Noopept share a neurotrophic-signaling mechanism and an unapproved US status, but Semax is distinguished by its activation-and-neuroprotection emphasis and its intranasal ACTH-analog origin, contrasted with Selank's anxiolytic focus and Noopept's oral cognitive-enhancer profile.
Because Semax sold outside its country of approval is an unregulated research chemical, quality is not a given and the burden of verification falls entirely on the buyer, a fundamentally weaker position than purchasing an approved medicine. The literature and gray-market sourcing reviews describe the strongest available signal of quality as independent analytical testing, and treat missing or generic documentation as a common warning sign.
With Semax sold as an unregulated research chemical, a third-party certificate of analysis by HPLC and mass spectrometry is the strongest documented quality signal, while missing certificates, suspiciously low prices, and untraceable vendors are recognized red flags.
Educational use only. This article describes what the published scientific and clinical literature reports about Semax. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
